Intensity Therapeutics, a privately held clinical-stage, biotechnology company developing proprietary cancer immunotherapy products, reports patents in the US and Australia.

“Intensity’s DfuseRxSM  platform has identified our lead drug, INT230-6. This novel product, now in clinical trials, has shown great promise in regressing tumors and extending life in animal models of metastatic cancer,” said Intensity’s President and CEO, Lewis H. Bender.

“A newly issued U.S. patent and soon-to-be issued Australian patent allow us to protect our unique technology. The Company now has multiple issued patents and several patent applications in the U.S. and countries around the world.”